Bullet flag-united-kingdom flag-ireland

THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN THE UK & IRELAND*

  • COVID-19
  • Cystic Fibrosis

Impact of COVID-19 on Cystic Fibrosis Clinical Trials

In this webinar, Dr Damian Downey gives an overview on the impact of COVID-19 on Cystic Fibrosis clinical trials. This includes the ramifications of the pandemic on trial sponsors, participants, regulatory requirements, changing practice and research sites. He explores the challenge of patients being drafted from Cystic Fibrosis studies into those associated with COVID-19 and poses the question about how to maintain integrity for those pre-pandemic, ongoing, trials.

Additionally, Dr Downey presents a summary of ECFS-CTN survey results on the impact of SARS-CoV2 on clinical research.

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

Dr Damian Downey

Dr Downey is an academic cystic fibrosis physician at Queen’s University Belfast and the N. Ireland Regional Adult CF Centre in Belfast. He trained in CF and Respiratory Medicine in Belfast, Manchester and Brisbane. His research focus is to optimise clinical response to established and new therapies and leads an active investigator-initiated and pharmaceutical-sponsored research program to help realise this. He is co-director of the European CF Clinical Trials Network.